Information Density: Fresenius SE & Co. KGaA – Signal Evidence & AI Readability

Resolutions of the 2026 Annual General Meeting

Acting together for sustainable impact: Sustainability Highlights Magazine Vol. 3 is online!

How Fresenius turns science into better patient care

More time for patients thanks to AI in the consulting room

FRESENIUS SE & CO. KGaA

Resolutions of the 2026 Annual General Meeting

Here you will find the resolutions of the 2026 Fresenius Annual General Meeting.

More details

Acting together for sustainable impact: Sustainability Highlights Magazine Vol. 3 is online!

Discover how Fresenius embeds sustainability into its core business and steers impact across clear focus topics – driven by shared responsibility and long‑term value creation.

Sustainability Highlights Magazine Vol. 3

How Fresenius turns science into better patient care

Explore how Fresenius leverages scientific innovation, collaboration, and evidence-based medicine to improve patient care. Discover inspiring patient stories and research projects from our business segments.

Read the story

More time for patients thanks to AI in the consulting room

With Scribe, our Quirónsalud hospitals are revolutionizing the Spanish healthcare system. The Ai-powered application enhances efficiency and quality while also strengthening the doctor–patient relationship – for more humanity in medicine.

Read the story

Fresenius Kabi

Products for critically and chronically ill patients

Fresenius Helios

Europe's leading private healthcare provider

[H2]
News

Brief News

[H3]
AI assistant enhances access to Investor Relations information

Today, Fresenius has launched the AI-powered assistant – “AskFRE” – on its Investor Relations (IR) website, marking an important step in advancing its digital capital markets communications. The solution is a joint initiative of the Fresenius AI Center of Excellence and the Investor Relations team.With AskFRE, visitors can now interact with an integrated AI chatbot that provides direct answers to capital market-relevant information. This includes financial results, company updates and other IR content – based exclusively on publicly available Fresenius disclosures.In an increasingly fast-paced and data-driven environment, digital investor relations play a key role in delivering timely, transparent and stakeholder-focused communication. AskFRE supports this ambition by enabling more intuitive access to financial information and tailored user interactions, while reinforcing the consistency and accessibility of Fresenius’ disclosures.With AskFRE, Fresenius underscores its commitment to advancing a best in class digital investor relations experience.AskFRE is now available: https://www.fresenius.com/AskFRE-Your-IR-Assistant

May 26, 2026 · Fresenius

2026 Annual General Meeting of Fresenius: Shareholders approve all agenda items

[H3]
2026 Annual General Meeting of Fresenius: Shareholders approve all agenda items
May 22, 2026 · Fresenius

2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends

[H3]
2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends
Michael Sen, CEO of Fresenius, emphasized: “In the past financial year, we showed that Fresenius can deliver a strong performance even in an environment where volatility has become the norm.”

May 22, 2026 · Fresenius

#FutureFresenius: REJUVENATE in action – Excellent start to the year - demonstrating continued strength and resilient performance; Guidance reconfirmed

[H3]
#FutureFresenius: REJUVENATE in action – Excellent start to the year - demonstrating continued strength and resilient performance; Guidance reconfirmed
Michael Sen, CEO of Fresenius: "Fresenius made an excellent start to 2026, delivering performance fully in line with our expectations and leading us to reconfirm our full‑year guidance.

May 06, 2026 · Fresenius

Fresenius invests in Avelios Medical and further expands its strategic partnership with SAP

[H3]
Fresenius invests in Avelios Medical and further expands its strategic partnership with SAP
Fresenius, together with SAP, is investing in Avelios Medical, a company developing a next-generation, cloud-native hospital information system.

May 06, 2026 · Fresenius

#FutureFresenius is paying off: S&P Global Ratings revises outlook for Fresenius SE from stable to positive

[H3]
#FutureFresenius is paying off: S&P Global Ratings revises outlook for Fresenius SE from stable to positive
S&P Global Ratings (S&P), a globally recognized credit rating agency today revised its credit outlook for Fresenius SE from stable to positive.

April 08, 2026 · Fresenius

Brief News

[H3]
Fresenius publishes 2025 Annual Report – REJUVENATE: Delivering accelerated performance for long-term value creation

Today, Fresenius published its 2025 Annual Report. As announced in late February 2026, 2025 marked another strong year of performance and the launch of the current phase of the #FutureFresenius strategy: Rejuvenate. Despite headwinds, the healthcare group achieved its outlook, which was raised twice during the year. Group revenue before special items rose to €22.6 billion, with organic growth of 7%, while constant currency Core EPS (excluding FMC) increased by 12%. “Over the past three years, we have successfully implemented our #FutureFresenius strategy and created a new Fresenius that is innovative, relevant, resilient, and adaptable. At the same time, we have significantly bolstered our company’s economic strength. We aim to build on this strong foundation,” said Michael Sen, Chairman of the Management Board of Fresenius. The 2025 Annual Report demonstrates how Fresenius is creating sustainable value for all stakeholders by executing its #FutureFresenius strategy. It includes the Sustainability Statement in accordance with the European Sustainability Reporting Standards (ESRS), and is available as a PDF and as an interactive online version in German and English. The online report features additional business stories and includes a video statement from CEO Michael Sen.

March 25, 2026 · Fresenius

#FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery

[H3]
#FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery
February 25, 2026 · Fresenius

Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years --- Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026

[H3]
Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years --- Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026
The Fresenius Supervisory Board has unanimously extended ahead of schedule the mandate of CEO Michael Sen (57) by five years. This will help to ensure continuity in the company’s leadership for the next phase in its #FutureFresenius strategy. His contract will now run until 2031.Wolfgang Kirsch, Chair of the Supervisory Board of Fresenius, said: “Michael Sen has been instrumental in driving the company’s development with #FutureFresenius in the past three years. Today, Fresenius is more innovative and relevant – well positioned to leverage the significant opportunities in the healthcare industry. Michael Sen and his team have placed Fresenius on a growth path offering long-term profitability that benefits all stakeholders. We want to maintain this continuity. Both the Supervisory Board and I personally look forward to continuing our collaboration in the coming years.”“I would like to thank the Supervisory Board for its trust and look forward to continuing to work with all Supervisory Board members, my management team, and our outstanding employees as well as our customers, partners, and shareholders. Over the past few years, we have made the company more innovative while remaining focused on delivering profitable growth. Today, Fresenius is more relevant than ever before. We want to continue this success story. In times of fundamental change shaped by rapid advances in new technologies such as AI and a transactional world order, we bear even greater responsibility as a leading global healthcare company. Now more than ever, our goal is to provide high-quality, reliable healthcare while making healthcare systems even more efficient and resilient,” adds Michael Sen, CEO of Fresenius.Dr. Christian Pawlu succeeds Robert MöllerThe Fresenius Supervisory Board has also unanimously appointed Dr. Christian Pawlu (48) to the Fresenius Management Board, effective July 1, 2026. He will oversee the businesses of Fresenius Helios, which includes the two private hospital chains, Quirónsalud in Spain and Helios Kliniken in Germany. He will succeed Robert Möller (59) on the Management Board, who will establish the company’s Office of the Management in Berlin and Brussels.“On behalf of the Supervisory Board, I would like to sincerely thank Robert Möller for the excellent cooperation and successful leadership of Fresenius Helios in recent years. Through the formation of medical clusters and the focus on digitalization and excellent patient care, the two hospital chains are excellently positioned in Germany and Spain. I am therefore delighted that Robert Möller will continue to contribute his expertise to the company,” says Wolfgang Kirsch. He adds: “With Christian Pawlu, we have been able to acquire a physician and strategist with a broad international network for the Group’s Management Board. I am especially pleased that we could find an outstanding internal candidate who has already contributed significantly to the hospital business as Chief Operating Officer of Fresenius Helios. I wish Christian Pawlu a strong start in his new role.”Michael Sen (57) has been CEO of Fresenius since October 1, 2022. He is also Chairman of the Supervisory Board of the listed dialysis provider Fresenius Medical Care. In April 2021, Michael Sen was appointed CEO of Fresenius Kabi. Before joining Fresenius, he was a member of the Management Board at Siemens AG, responsible for the healthcare and energy business. He took Siemens Healthineers public during this time. Prior to this, he was Chief Financial Officer at the energy group E.ON SE.Dr. Christian Pawlu has been Chief Operating Officer (COO) of Helios in Germany since March 2025, and in September 2025 expanded his responsibilities as COO of Fresenius Helios including Helios in Germany and Quirónsalud in Spain. Prior to this, he served as Head of Corporate Development at Fresenius after joining Fresenius Kabi in Bad Homburg as Head of Corporate Development in April 2021. From 2022 to 2025, he was a member of the Supervisory Board of the Fresenius subsidiary mAbxience, based in Spain. In his early career, Christian Pawlu was a member of Sandoz Group AG’s Executive Board, CEO of a private high-tech start-up, and a partner at McKinsey & Company management consultancy.

February 25, 2026 · Fresenius

Brief News

[H3]
Fresenius and Phlow Partner to Strengthen U.S. Supply of Essential Medicine

Fresenius Kabi, an operating company of Fresenius, has entered a first-of-its-kind partnership with U.S. manufacturer Phlow Corp. to establish a fully domestic, end-to-end supply chain for Epinephrine Injection, USP — an FDA designated essential medicine frequently at risk of shortage in the United States. Under the collaboration, Phlow will produce the U.S.-based API, while Fresenius Kabi manufactures the finished doses for hospitals and clinics across the country. With this initiative, Fresenius advances its local-for-local manufacturing strategy and supports national efforts to strengthen pharmaceutical security. The partnership reinforces the ambitions of #FutureFresenius as it expands Fresenius’ role as a leading global provider of lifesaving therapies, advancing resilient manufacturing that improves patient care and health-system stability. Pending regulatory approvals, epinephrine produced through this collaboration could be available to U.S. hospitals in 2027.

February 09, 2026 · Fresenius Kabi

AI in Healthcare: SAP and Fresenius Accelerate Digital Healthcare Delivery

[H3]
AI in Healthcare: SAP and Fresenius Accelerate Digital Healthcare Delivery
January 19, 2026 · Fresenius

Brief News

[H3]
Fresenius advances scalable cell therapy manufacturing with strategic-development agreement

Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments. Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development. The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation. By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care.

January 14, 2026 · Fresenius Kabi

Brief News

[H3]
Sale of Austrian project business and spa operations to PORR approved

The sale of the Austrian project business and spa operations of VAMED Vitality World to PORR, announced by Fresenius in October 2025, has received the necessary approvals and will be completed on December 31, 2025.

December 23, 2025 · Fresenius

Brief News

[H3]
Fresenius strengthens biomanufacturing capabilities through AI collaboration

mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable.The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faste

[H1]
Annual General Meeting

To archive

Contact

Nick Stone

Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com

Share Price
FRESENIUS SE & CO. KGaA

Data is delayed by 15 minutes.
Share Price Information

Shareholder Portal

[IMG: shareholder portal]

To Shareholder Portal

Related Links

Interactive Tool

Total Return Calculator

FAQ

Shares and dividends

Annual General Meeting

The Annual General Meeting of Fresenius SE & Co. KGaA took place on May 22, 2026, at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany.

[H3] Shareholder Portal of Fresenius SE & Co. KGaA
Shareholders can use the Shareholder Portal to exercise their voting right by electronic postal ballot, authorize third parties or authorize and instruct the proxies nominated by the Company. The login credentials to the Shareholder Portal are indicated on the admission ticket shareholders receive after due registration to the Annual General Meeting. To Shareholder Portal

Internet broadcast

The opening of the Annual General Meeting by the Chairman of the Supervisory Board, Wolfgang Kirsch, and the report by the Chairman of the Management Board, Michael Sen, were broadcast publicly.

[H2]

Speech of CEO Michael Sen

Watch replay
CEO Speech (PDF, 270KB)
Presentation (PDF, 6.30MB)

Download All

[H2]
Information on the Annual General Meeting on May 22, 2026

Chairman Letter and Speech Wolfgang Kirsch

Chairman Letter (PDF, 294KB)
Chairman Speech (PDF, 186KB)

Download All

[H2]

Invitation / Agenda

Agenda (PDF, 329KB)

Information for shareholders

Information on rights of shareholders (PDF, 187KB)
Form for shareholders to authorize a proxy and to issue instructions (PDF, 245KB)
Privacy Notice (PDF, 25KB)
Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 183KB)

Information on the Agenda items

Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2025 (HGB) (PDF, 7.68MB)
Fresenius Group Annual Report 2025 (PDF, 14.08MB)
Compensation Report 2025 (PDF, 616KB)
Proposal of the General Partner and the Supervisory Board on the allocation of the distributable profit for the financial year 2025 (Agenda item 2) (PDF, 118KB)
Further Information on agenda item 7 – Remuneration of the Supervisory Board (PDF, 85KB)
General Partner’s report regarding Agenda item 8 (PDF, 87KB)
General Partner’s report regarding Agenda item 10 (PDF, 86KB)
General Partner’s report regarding Agenda items 11 and 12 (PDF, 136KB)
Further information on Agenda item 13 – Frequently Asked Questions (FAQ) on the Conversion from Bearer Shares to Registered Shares (PDF, 107KB)
Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 139KB)
Articles of Association Fresenius SE & Co. KGaA (May 23, 2025) (PDF, 174KB)
Revised version of the Articles of Association with amendments highlighted - Amendments to the Articles of Association regarding Agenda items 7–10 and 13–15 (PDF, 169KB)

Additional Information

Meeting Participation by individual Supervisory Board member 2025 (PDF, 107KB)
2025 SASB Mapping (PDF, 309KB)
Information pursuant to Table 8 of the Commission Implementing Regulation (EU) 2018/1212 (PDF, 494KB)

Further publications

Dividend announcement (PDF, 473KB)
Voting results 2026 (PDF, 75KB)

Download All

[H3]
Countermotions and election proposals
Below, you find the countermotions from a shareholder within the meaning of section 126 of the German Stock Corporation Act (Aktiengesetz) on items 3 and 4 of the agenda of the Annual General Meeting of Fresenius SE & Co. KGaA on May 22, 2026.

[H2]

Countermotions and election proposals

Annual General Meeting 2026 Countermotions from shareholders (PDF, 325KB)

Download All

[H4] Archive

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

The Annual General Meeting of Fresenius SE & Co. KGaA took place on May 23, 2025, at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany.

Annual General Meeting on May 23, 2025

[H2]

Speech of CEO Michael Sen

Watch replay
Speech of CEO (PDF, 172KB)
Presentation (PDF, 8.84MB)

Download All

[H2]

Chairman Letter Wolfgang Kirsch

Chairman Letter (PDF, 242KB)

Download All

[H2]

Invitation / Agenda

Agenda (PDF, 1.30MB)

Download All

[H2]

Information for shareholders

Information on rights of shareholders (PDF, 184KB)
Form for shareholders to authorize a proxy and to issue instructions (PDF, 157KB)
Privacy Notice (PDF, 69KB)
Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 241KB)

Information on the agenda items

Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2024 (HGB)
(PDF, 2.92MB)
Fresenius Group Annual Report 2024 (PDF, 11.26MB)
Compensation Report 2024 (PDF, 589KB)
Proposal of the General Partner and the Supervisory Board on the allocation of the distributable profit for the financial year 2024 ended on December 31, 2024 (Agenda item 2) (PDF, 83KB)
Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 151KB)
Further Information on agenda item 7 – Remuneration of the Supervisory Board (PDF, 83KB)
Further information on agenda items 8 and 9 – CVs (PDF, 1.08MB)
Articles of Association Fresenius SE & Co. KGaA (April 2024) (PDF, 171KB)

Additional Information

Meeting Participation by individual Supervisory Board member 2024 (PDF, 142KB)
2024 SASB Mapping (PDF, 163KB)

Further publications

Dividend announcement (PDF, 95KB)
Voting results 2025 (PDF, 35KB)

Download All

[H4]
Countermotions and election proposals
Below, you find the countermotions from a shareholder within the meaning of section 126 of the German Stock Corporation Act (Aktiengesetz) on items 3 and 10 of the agenda of the Annual General Meeting of Fresenius SE & Co. KGaA on May 23, 2025.

[H2]

Countermotions and election proposals

Annual General Meeting 2025 Countermotions from shareholders (PDF, 138KB)

Download All

[H4]
Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)
At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights.

The Annual General Meeting of Fresenius SE & Co. KGaA  took place on Friday, 17 May 2024 at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany.

Annual General Meeting on May 17, 2024

[H2]

Speech of CEO Michael Sen

Speech of CEO (PDF, 350KB)
Presentation (PDF, 5.45MB)

Download All

[H2]

Chairman Letter Wolfgang Kirsch

Chairman Letter (PDF, 274KB)

Download All

[H2]

Invitation / Agenda

Agenda (PDF, 1,004KB)

Information for shareholders

Information on rights of shareholders (PDF, 138KB)
Form for shareholders to authorize a proxy and to issue instructions (PDF, 173KB)
Privacy Notice (PDF, 70KB)
Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 197KB)

Information on the agenda items

Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2023 (HGB) (PDF, 2.26MB)
Fresenius Group Annual Report 2023 (PDF, 9.23MB)
Compensation Report 2023 (PDF, 294KB)
Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 128KB)
Articles of Association Fresenius SE & Co. KGaA (June 15, 2023) (PDF, 195KB)

Additional Information

Meeting Participation by individual Supervisory Board member 2023 (PDF, 83KB)
2023 SASB Mapping (PDF, 214KB)
2023 TCFD Index (PDF, 104KB)

Download All

[H2]

Further publications

Voting results 2024 (PDF, 269KB)

Download All

[H3]
Countermotions
Currently, there are no countermotions.

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)
At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights.

The virtual Annual General Meeting of Fresenius SE & Co. KGaA took place on May 17, 2023.

Virtual Annual General Meeting on May 17, 2023

[H2]

Speech of CEO Michael Sen

Watch replay
Speech of CEO (PDF, 397KB)

Download All

[H2]

Invitation / Agenda

Agenda (PDF, 3.44MB)

Information for shareholders

Information on rights of shareholders (PDF, 162KB)
Form for shareholders to authorize a proxy and to issue instructions (PDF, 152KB)
Privacy Notice (PDF, 99KB)
Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 193KB)
Recommendations/instructions for electronic connection via video (PDF, 107KB)

Information on the agenda items

Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2022 (HGB) (PDF, 2.44MB)
Fresenius Group Annual Report 2022 (PDF, 10.87MB)
Compensation Report 2022 (PDF, 2.56MB)
Proposal of the General Partner and the Supervisory Board on the allocation of the distributable profit for the financial year 2022 ended on December 31, 2022 (Agenda item 2) (PDF, 93KB)
Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 154KB)
Further information regarding the Compensation System 2023+ (Agenda item 7) (PDF, 551KB)
Articles of Association Fresenius SE & Co. KGaA (July 6, 2022) (PDF, 168KB)

Additional Information

Meeting Participation by individual Supervisory Board member 2022 (PDF, 104KB)
2022 SASB Mapping (PDF, 206KB)
2022 TCFD Index (PDF, 73KB)

Further publications

Dividend announcement (PDF, 119KB)
Voting results 2023 (PDF, 285KB)

Download All

[H3]
Countermotions
Currently, there are no countermotions.

Total number of shares and of voting rights at the time of the convocation (Section 124 a sentence 1 no. 4 of the German Stock Corporation Act)
At the time the General Meeting is convened, 563,237,277 ordinary shares out of a total of 563,237,277 ordinary shares issued carry rights of participation and voting rights.

The virtual Annual General Meeting 2022 of Fresenius SE & Co. KGaA took place on May 13, 2022.

Virtual Annual General Meeting on May 13, 2022

[H2]

Speech of CEO Stephan Sturm

Watch replay
Speech of CEO (PDF, 207KB)
Presentation (PDF, 4.00MB)

Download All

[H2]

Invitation / Agenda

Agenda (PDF, 4.90MB)

Information for shareholders

Information on rights of shareholders (PDF, 128KB)
Form for shareholders to authorize a proxy and to issue instructions (PDF, 173KB)
Privacy Notice (PDF, 71KB)
Information pursuant to § 125 Stock Corporation Act (AktG) in conjunction with the Commission Implementing Regulation (EU) 2018/1212 (“EU-IR”) (PDF, 194KB)

Information on scrip dividend

Supplemented prospectus exemption document, 2nd supplement (PDF, 258KB)
Supplemented prospectus exemption document, 1st supplement (PDF, 255KB)
Prospectus exemption document (PDF, 328KB)
Information document (PDF, 243KB)
Subscription Offer (PDF, 212KB)
Announcement of subscription price (PDF, 107KB)

Information on the agenda item

Financial Statements and Management Report of Fresenius SE & Co. KGaA as of December 31, 2021 (HGB) (PDF, 2.14MB)
Fresenius Group Annual Report 2021 (PDF, 12.98MB)
Compensation Report 2021 (PDF, 4.71MB)
Proposal of the General Partner and the Supervisory Board on the allocation of the distributable profit for the financial year 2021 ended on December 31, 2021 (Agenda item 2) (PDF, 77KB)
General Partner’s written report regarding Item 9 of the agenda (PDF, 94KB)
General Partner’s written report regarding Item 10 of the agenda (PDF, 96KB)
General Partner’s written report regarding Item 11 and 12 of the agenda (PDF, 122KB)
Explanatory Report of the General Partner of Fresenius SE & Co. KGaA (Fresenius Management SE) on the Statements pursuant to Section 289a Para. 1, Section 315a Para. 1 of the German Commercial Code (Handelsgesetzbuch – HGB) (PDF, 149KB)
Articles of Association Fresenius SE & Co. KGaA (PDF, 253KB)

Additional Information

Further information on the Compensation Report 2021 (PDF, 674KB)
Meeting Participation by individual Supervisory Board member 2021 (PDF, 96KB)
2021 SASB Mapping (PDF, 190KB)
2021 TCFD Index (PDF, 119KB)

Further publications

Dividend announcement (PDF, 107KB)
Voting results 2022 (PDF, 288KB)

Download All

[H4]
Countermotions and election proposals
Below, you find the count

[H1]
Contacts

Related Links

Group Overview

The Healthcare Group worldwide

Fresenius-Websites

Do you have questions regarding our company and our products and services? Our experts will be happy to help.

Fresenius SE & Co. KGaAElse-Kröner-Str. 161352 Bad HomburgGermanyT: +49 6172 608-0

Postal address:Fresenius SE & Co. KGaA61346 Bad HomburgGermany

How to get here (PDF, 2.01 MB)
Route planner

Contacts for investors and analysts

Nick Stone
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com

Karen Janek
Assistant Investor Relations
T: +49 (0) 6172 608-2487
karen.janek@fresenius.com

Florian Feick
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com

Stefanie Drees
Director Investor Relations
T: +49 (0) 6172 608-5211
stefanie.drees@fresenius.com

Michael Otto
Director Investor Relations
T: +49 (0) 6172 608-2419
michael.otto@fresenius.com

Elisabeth Truckenbrodt
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com

Felix Klein
Director Investor Relations
T: +49 (0) 6172 608-96484
felix.klein@fresenius.com

Kacper Boborykin
Director Investor Relations
(US based)
T: +1 224 566 1998
kacper.boborykin@fresenius.com

Mara Sinsel
Senior Manager Investor Relations
T: +49 (0) 6172 608-96538
mara.sinsel@fresenius.com

Luca Thorißen
Senior Manager Investor Relations
T +49 6172 608-97049
luca.thorissen@fresenius.com

Elisabeth Jung
Senior Manager Investor Relations
T: +49 (0) 6172 608-2421
elisabeth.jung@fresenius.com

Annette Hainz
Manager Investor Relations
T: +49 (0) 6172 608-2604
annette.hainz@fresenius.com

Contacts for the media

Alexandra Graulich
Secretary Group Communications
T: +49 (0) 6172 608-2501
alexandra.graulich@fresenius.com

Contacts for Corporate Topics

Timo Lindemann
T +49 (0) 6172 608-7939
timo.lindemann@fresenius.com

Leif Heussen
T +49 (0) 6172 608-4030
leif.heussen@fresenius.com

Annette Schönleber
T: +49 (0) 6172 608-96847
annette.schoenleber@fresenius.com

Sabine Polte (on parental leave)
T: +49 (0) 6172 608-2395
sabine.polte@fresenius.com

Contacts for Fresenius Kabi

Nicole Meier
T +49 (0) 6172 686-2394
nicole.meier@fresenius.com

Tim-Arne Kuehrt
T +49 (0) 6172 686-4112
tim.kuehrt@fresenius.com

Contacts for Fresenius Helios

Steffen Rinas
T: +49 (0) 6172 608-6698
steffen.rinas@fresenius.com

Birgit Gugath
T +49 (0) 173 28 12 169
birgit.gugath@helios-gesundheit.de

Franziska Vallentin
T +49 (0) 151 65 21 99 81
franziska.vallentin@helios-gesundheit.de

Contacts for applicants

If you have questions regarding our application process or our career opportunities please contact us at karriere@fresenius.com.
You can find detailed contact information on our careers website.

Contacts for health care professionals and patients

For information on specific products and services, please directly contact our business segments:
Fresenius Kabi
Infusion therapy, clinical nutrition and transfusion technology
Fresenius Helios (German only)
Hospitals and health care prevention

Contacts for Governmental Affairs & Public Policy

Joachim Weith
Senior Vice President Governmental Affairs & Public Policy
T: +49 (0) 6172 608-2101
GAPP@fresenius.com

Daniela Eyrich
Team Assistant Governmental Affairs & Public Policy
T: +49 (0) 6172 608-2302
daniela.eyrich@fresenius.com

Contacts for questions about sustainability

If you have any questions about sustainability, please contact us at the following address: sustainability@fresenius.com

Detailed information on sustainability can be found at Responsibility.

Contact for procurement inquiries

If you have any questions about procurement, please contact us at the following address: zentraleinkauf@fresenius.com

Related Links

Group Overview

The Healthcare Group worldwide

Fresenius-Websites

[H1]
Fresenius Kabi

Industrial production of infusion solutions at Fresenius Kabi's plant in Friedberg.

Contact

Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com

Fresenius Kabi

Related Links

Infusion Therapy

Clinical Nutrition

Transfusion Technology

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.

Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition portfolio includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more. Fresenius Kabi employs over 40,000 people worldwide. In 2025 the company reported sales of more than €8.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius.

Contact

Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com

Fresenius Kabi

Related Links

Infusion Therapy

Clinical Nutrition

Transfusion Technology